Pharma Pulse 7/2/25: The Impact of FDA’s Ban on Compounded GLP-1s; How Sites and Sponsors Are Adapting to Clinical Trial Budget Cuts
The Impact of FDA’s Ban on Compounded GLP-1s
A Pharmaceutical Executive article explores how the FDA’s ban on compounded semaglutides—following stabilized supply from Novo Nordisk and Eli Lilly—has significantly disrupted access for patients who relied on these lower-cost alternatives, prompting Olympia Pharmaceuticals to shift its focus to legal and in-demand options like liraglutide.
How Sites and Sponsors Are Adapting to Clinical Trial Budget Cuts
In an interview with Applied Clinical Trials, Trially CEO Kyle McAllister discussed how clinical trial sites and sponsors are adapting to budget cuts by leveraging technologies such as AI and telemedicine but warned that reduced staffing and the shift toward industry-sponsored studies may compromise research diversity and long-term infrastructure.
Pharmacists Have a Crucial Role Helping Patients With ATTR-CM Navigate Treatment With Tafamidis
Pharmacists play a critical role in helping patients with transthyretin amyloid cardiomyopathy manage treatment with tafamidis by providing education, ensuring adherence, navigating cost and access barriers, and counseling on key safety and dosing considerations, as ongoing research continues to explore the drug’s long-term benefits and potential in broader patient populations.
Q&A: Pharmacies Grapple With Patient Influx Amid Rite Aid Closures
As Rite Aid shutters hundreds of stores amid bankruptcy, independent pharmacies are struggling to absorb displaced patients due to poor reimbursement rates, staffing shortages, and financial strain—prompting calls for diversification into clinical services like immunizations and medication therapy management to survive the ongoing shift in pharmacy care.
The FDA is evaluating potential regulatory action on argenx’s Vyvgart Hytrulo following reports of severe disease worsening in some CIDP patients, but analysts and the company emphasize that the signal is limited, not new, and unlikely to impact the drug’s overall benefit-risk profile or lead to major label changes.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
